Champions Oncology details unaudited Q2 2025 financial results

Champions Oncology, Inc. filed a current report to disclose that on December 15, 2025 it issued a press release announcing its unaudited financial results for its second quarter ended October 31, 2025.

Rhea-AI Filing Summary

Champions Oncology, Inc. filed a current report to disclose that on December 15, 2025 it issued a press release announcing its unaudited financial results for its second quarter ended October 31, 2025.

The press release is attached as Exhibit 99.1, and the company states that the financial information described under Item 2.02 is being furnished rather than filed, and will only be incorporated into other securities filings if specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event did Champions Oncology (CSBR) report in this filing?

Champions Oncology reported that on December 15, 2025 it issued a press release announcing its unaudited financial results for its second quarter ended October 31, 2025.

Which period do the disclosed Champions Oncology (CSBR) results cover?

The press release provides unaudited financial results for Champions Oncology’s second quarter ended October 31, 2025.

Are the Champions Oncology (CSBR) second-quarter results audited or unaudited?

The company describes the second-quarter financial figures in the press release as unaudited financial results.

Where can investors find the detailed Champions Oncology (CSBR) Q2 2025 results?

The detailed numbers are contained in the company’s press release attached as Exhibit 99.1 to this report.

Is the financial information in this Champions Oncology report considered filed with the SEC?

The company states that the information under Item 2.02 is furnished, not filed, and will only be included in other securities filings if specifically incorporated by reference.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/15/2025 - 04:14 PM EST Learn about SEC filing dates

0000771856false00007718562025-12-152025-12-15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 15, 2025

CHAMPIONS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-11504

52-1401755

(State or Other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

Identification No.)

1 University Plaza, Suite 307, Hackensack, New Jersey 07601

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (201) 808-8400

N/A

(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

CSBR

The Nasdaq Stock Market LLC

    

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

INFORMATION TO BE INCLUDED IN THE REPORT

Item 2.02. Results of Operations and Financial Condition.

On December 15, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its second quarter ended October 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

The following exhibit is filed herewith:

Exhibit No.

99.1 Press Release dated December 15, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						CHAMPIONS ONCOLOGY, INC.
						(Registrant)
Date: December 15, 2025			By:			/s/ Robert Brainin
						Robert Brainin
						Chief Executive Officer